IRONWOOD PHARMACEUTICALS INC (IRWD): debt financing — Ironwood completes $1.15B tender offer for VectivBio, acquires ~97.6% of shares

IRONWOOD PHARMACEUTICALS INC

Tendered 59.3M shares represent ~94.4% plus 2.0M via guaranteed delivery (~97.6% total).
Offer price $17/share cash; total consideration ~$1.15B.
Borrowed $400M under Revolving Credit Agreement to fund portion.
Plans to delist VectivBio shares from Nasdaq and execute Swiss squeeze-out merger.
Ironwood appointed new directors to VectivBio board effective immediately.

item 2.01 item 2.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

IRONWOOD PHARMACEUTICALS INC incurred revolving credit of $400,000,000 with Wells Fargo Bank, N.A..

Instrument: revolving credit
Principal: $400,000,000
Counterparty: Wells Fargo Bank, N.A.
Event: incurrence

Exact text from the filing

On June 29, 2023, Ironwood borrowed $400,000,000 under the Revolving Credit Agreement to fund a portion of the consideration paid to purchase the Shares in connection with the Offer.

View on SEC.gov

222 debt financings filed in the last 30 days. Browse all debt financings →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-077076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.